Streetbeat News

Partnerships

JAGX

Jaguar Health, Inc. (NASDAQ:JAGX) has entered into a 5-year exclusive in-license agreement with Venture Life Group PLC for the FDA-approved oral mucositis product, Gelclair, targeting the U.S. market. Gelclair, aimed at managing pain and providing relief for oral mucositis patients, marks Jaguar's expansion into cancer supportive care. The commercial launch is planned for Q3 2024. Oral mucositis is a common side effect of cancer treatments, affecting up to 40% of chemotherapy patients and 90% of those with head and neck cancers undergoing chemotherapy and radiotherapy.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:35 pm

SSYS

Stratasys has signed an agreement to become the exclusive polymer 3D printing partner of Select Additive Technologies, marking the first time the largest machine tool reseller in the US will offer additive manufacturing benefits to its extensive customer base.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:25 pm

VUZI

Vuzix's subsidiary, Moviynt, has entered into a partnership with NetLogistik, although the terms of the partnership have not been disclosed. This strategic move could potentially enhance Vuzix's market position and offerings.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:22 pm

BLND

Michigan Schools and Government Credit Union (MSGCU) has chosen Blend's cloud banking services to improve its digital lending experience. This partnership will focus on enhancing the mortgage, income, close, and home equity solutions for MSGCU, aiming to simplify the application process, automate lender workflows, and ensure a consistent digital experience across its real estate business.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:22 pm

OPTT

Ocean Power Technologies, Inc. (OPTT) has entered into a teaming agreement with a major international defense contractor to deploy its Maritime Domain Awareness Solutions (MDAS) in certain geographic regions. This collaboration aims to enhance maritime security and surveillance capabilities through OPT's innovative technology and the contractor's defense expertise. No financial terms of the agreement were disclosed.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:21 pm

GIL

Browning West, holding 5% of Gildan Activewear's shares, criticizes CEO Vince Tyra's strategy and governance, highlighting his track record of value destruction and underwhelming plans for the company. They propose electing eight new directors at the 2024 shareholder meeting to implement a value creation strategy, contrasting Tyra's approach with speculative spending and poor capital allocation. Browning West's plan aims to increase operating margins and shareholder returns, setting specific targets for share price growth.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:12 pm

SABR

Air Serbia is advancing its strategic growth and enhancing customer experience by adopting Sabre Corporation's advanced revenue and passenger service solutions. This move is aimed at improving operational efficiency and providing a more personalized service to passengers, leveraging Sabre's technology to optimize revenue streams and enhance the overall travel experience.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:06 pm

KNTK

Infinium and Kinetik Holdings Inc. (NYSE:KNTK) have entered into a long-term agreement for the purchase of CO2 for eFuels production. This partnership aims to advance decarbonization in heavy transport and chemical industries by utilizing CO2 from Kinetik's Permian Basin operations for Infinium's Project Roadrunner, which focuses on producing sustainable aviation fuel (eSAF). The agreement highlights both companies' commitment to sustainability and the reduction of carbon emissions, with Kinetik dedicating CO2 from its West Texas facility and Infinium receiving a $75 million equity commitment from Breakthrough Energy Catalyst.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:02 pm

CVAC

CureVac and MD Anderson have announced a strategic collaboration to develop novel cancer vaccines, aiming to leverage CureVac's mRNA technology for cancer treatment advancements.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:21 am

NBIX

VYGR

Voyager Therapeutics is set to receive a $3M milestone payment in Q2 of 2024, triggered by the selection of a development candidate.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:12 am